Active	Status	Sponsor type	Region	Phase	Filter
38 Active 1 Inactive 39 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

38 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bonella, Francesco
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF	Terminated	3	372	Europe, US, RoW	Pamrevlumab, FG-3019, Placebo	FibroGen	Idiopathic Pulmonary Fibrosis	09/23	09/23
IMPALA-2, NCT04544293 / 2020-001263-85: Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	Active, not recruiting	3	160	Europe, Canada, Japan, US, RoW	Molgramostim, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF), Placebo	Savara Inc., Savara ApS,	Autoimmune Pulmonary Alveolar Proteinosis	11/23	11/24
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease	Recruiting	3	440	Europe, Canada, Japan, US, RoW	Belimumab, BENLYSTA, GSK1550188, Placebo	GlaxoSmithKline	Lung Diseases, Interstitial	10/28	12/28
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis	Active, not recruiting	3	597	Europe, RoW	Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer	United Therapeutics	Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease	07/25	07/25
NCT05130970 / 2021-003162-12: Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis	Completed	2	81	Europe, Canada, US, RoW	Garadacimab, Factor XIIa antagonist monoclonal antibody, CSL312, Placebo	CSL Behring	Idiopathic Pulmonary Fibrosis	01/24	01/24
NCT06317285: A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)	Recruiting	2	150	Europe, Canada, US, RoW	GSK3915393, Placebo	GlaxoSmithKline	Idiopathic Pulmonary Fibrosis	03/26	03/26
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27
Hammerl, Peter
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Data from MATINEE trial for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD	Completed	3	806	Europe, Canada, US, RoW	Placebo, Mepolizumab	GlaxoSmithKline, PPD DEVELOPMENT, LP	Pulmonary Disease, Chronic Obstructive	08/24	08/24
NCT06317285: A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)	Recruiting	2	150	Europe, Canada, US, RoW	GSK3915393, Placebo	GlaxoSmithKline	Idiopathic Pulmonary Fibrosis	03/26	03/26
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27
NCT06154837: A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease	Recruiting	1	130	Europe, US	GSK3862995B, Placebo	GlaxoSmithKline	Pulmonary Disease, Chronic Obstructive	06/26	06/26
NCT03318406: Post-Market BTVA Registry	Recruiting	N/A	300	Europe	Bronchoscopic Thermal Vapor Ablation, BTVA, InterVapor	Uptake Medical Technology, Inc.	Emphysema or COPD	12/27	12/30
NCT05717192: BENTO - Bronchoscopic Lung Volume Reduction in Severe Emphysema Using Thermoablation	Recruiting	N/A	224	Europe	InterVapor®-System	IHF GmbH - Institut für Herzinfarktforschung	Emphysema or Chronic Obstructive Pulmonary Disease	04/26	12/27
Froidure, Antoine
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease	Recruiting	3	440	Europe, Canada, Japan, US, RoW	Belimumab, BENLYSTA, GSK1550188, Placebo	GlaxoSmithKline	Lung Diseases, Interstitial	10/28	12/28
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis	Active, not recruiting	3	597	Europe, RoW	Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer	United Therapeutics	Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease	07/25	07/25
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27
FIND-RA, NCT04002765: Factors of ILD in Newly Diagnosed Rheumatoid Arthritis	Recruiting	N/A	300	Europe	pulmonary function tests, High-resolution CT scanner	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	Rheumatoid Arthritis	12/22	12/22
Dahlqvist, Caroline
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease	Recruiting	3	440	Europe, Canada, Japan, US, RoW	Belimumab, BENLYSTA, GSK1550188, Placebo	GlaxoSmithKline	Lung Diseases, Interstitial	10/28	12/28
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis	Active, not recruiting	3	597	Europe, RoW	Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer	United Therapeutics	Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease	07/25	07/25
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27
Mackiewicz, Barbara
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27
NCT03870828: Clinical Characteristics of Interstitial Pneumonia With Autoimmune Features (IPAF) - a Multicenter Prospective Study	Not yet recruiting	N/A	210	Europe	Bronchoalveolar lavage and taking bronchial mucosa samples, 6minute walk test, 6MWT, Arterial blood gas, ABG, Blood drawing	Medical University of Silesia	Interstitial Lung Disease, Interstitial Pneumonia, Interstitial Fibrosis, Autoimmune Diseases	02/20	12/25
Tzouvelekis, Argyrios
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Data from MATINEE trial for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD	Completed	3	806	Europe, Canada, US, RoW	Placebo, Mepolizumab	GlaxoSmithKline, PPD DEVELOPMENT, LP	Pulmonary Disease, Chronic Obstructive	08/24	08/24
DESTINY, NCT05334368: Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial	Recruiting	3	123	Europe, Japan, US, RoW	Depemokimab, Placebo	GlaxoSmithKline	Hypereosinophilic Syndrome	11/26	11/26
PRECISION, NCT05926505 / 2023-000102-25: Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome	Recruiting	2/3	182	Europe	Placebo, Anakinra 149 MG/ML Prefilled Syringe [Kineret]	Hellenic Institute for the Study of Sepsis, Hellenic Institute for the Study of Sepsis	Post-Acute COVID-19 Syndrome, Post-Acute COVID-19, Long COVID	08/25	08/25
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27
Patyk, Iwona
BBT877-IPF-004, NCT05483907: To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF Jul 2023 - Dec 2023 : Interim data for the treatment of IPF Initiation of trial in idiopathic pulmonary fibrosis Nov 2022 - Nov 2022: Initiation of trial in idiopathic pulmonary fibrosis	Completed	2	129	Europe, US, RoW	BBT-877, Placebo	Bridge Biotherapeutics, Inc.	Idiopathic Pulmonary Fibrosis	01/25	02/25
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27
Gauthier, Patrice
NCT06372496: Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma	Active, not recruiting	4	1358	Canada, Japan, US, RoW	Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists	GlaxoSmithKline	Asthma	11/25	03/26
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease	Recruiting	3	440	Europe, Canada, Japan, US, RoW	Belimumab, BENLYSTA, GSK1550188, Placebo	GlaxoSmithKline	Lung Diseases, Interstitial	10/28	12/28
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27
Breyer, Marie-Kathrin
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27
NCT01727518: The Austrian LEAD (Lung hEart sociAl boDy) Study	Active, not recruiting	N/A	14966	Europe	As the LEAD study is an observational cohort study, there is no intervention to report.	Ludwig Boltzmann Institute for Lung Health	Respiration Disorders, Body Composition, Beneficial, Metabolic Health	10/16	10/28
NCT06522347: Mycobacteria Registry Study: Prospective Observational Study in Austria	Recruiting	N/A	1000	Europe		Ludwig Boltzmann Institute for Lung Health, Sigmund Freud PrivatUniversitat	Non-Tuberculous Mycobacterial Pneumonia, Tuberculosis	12/53	12/53
NCT06522334: Interstitial Lung Disease Registry Study: Prospective and Retrospective Observational Study in Austria	Recruiting	N/A	400	Europe		Ludwig Boltzmann Institute for Lung Health	Interstitial Lung Disease	02/34	02/34
Glaeser, Sven
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27
Tomos, Ioannis
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27
Manali, Efrosyni
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bonella, Francesco
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF	Terminated	3	372	Europe, US, RoW	Pamrevlumab, FG-3019, Placebo	FibroGen	Idiopathic Pulmonary Fibrosis	09/23	09/23
IMPALA-2, NCT04544293 / 2020-001263-85: Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	Active, not recruiting	3	160	Europe, Canada, Japan, US, RoW	Molgramostim, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF), Placebo	Savara Inc., Savara ApS,	Autoimmune Pulmonary Alveolar Proteinosis	11/23	11/24
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease	Recruiting	3	440	Europe, Canada, Japan, US, RoW	Belimumab, BENLYSTA, GSK1550188, Placebo	GlaxoSmithKline	Lung Diseases, Interstitial	10/28	12/28
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis	Active, not recruiting	3	597	Europe, RoW	Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer	United Therapeutics	Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease	07/25	07/25
NCT05130970 / 2021-003162-12: Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis	Completed	2	81	Europe, Canada, US, RoW	Garadacimab, Factor XIIa antagonist monoclonal antibody, CSL312, Placebo	CSL Behring	Idiopathic Pulmonary Fibrosis	01/24	01/24
NCT06317285: A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)	Recruiting	2	150	Europe, Canada, US, RoW	GSK3915393, Placebo	GlaxoSmithKline	Idiopathic Pulmonary Fibrosis	03/26	03/26
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27
Hammerl, Peter
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Data from MATINEE trial for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD	Completed	3	806	Europe, Canada, US, RoW	Placebo, Mepolizumab	GlaxoSmithKline, PPD DEVELOPMENT, LP	Pulmonary Disease, Chronic Obstructive	08/24	08/24
NCT06317285: A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)	Recruiting	2	150	Europe, Canada, US, RoW	GSK3915393, Placebo	GlaxoSmithKline	Idiopathic Pulmonary Fibrosis	03/26	03/26
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27
NCT06154837: A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease	Recruiting	1	130	Europe, US	GSK3862995B, Placebo	GlaxoSmithKline	Pulmonary Disease, Chronic Obstructive	06/26	06/26
NCT03318406: Post-Market BTVA Registry	Recruiting	N/A	300	Europe	Bronchoscopic Thermal Vapor Ablation, BTVA, InterVapor	Uptake Medical Technology, Inc.	Emphysema or COPD	12/27	12/30
NCT05717192: BENTO - Bronchoscopic Lung Volume Reduction in Severe Emphysema Using Thermoablation	Recruiting	N/A	224	Europe	InterVapor®-System	IHF GmbH - Institut für Herzinfarktforschung	Emphysema or Chronic Obstructive Pulmonary Disease	04/26	12/27
Froidure, Antoine
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease	Recruiting	3	440	Europe, Canada, Japan, US, RoW	Belimumab, BENLYSTA, GSK1550188, Placebo	GlaxoSmithKline	Lung Diseases, Interstitial	10/28	12/28
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis	Active, not recruiting	3	597	Europe, RoW	Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer	United Therapeutics	Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease	07/25	07/25
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27
FIND-RA, NCT04002765: Factors of ILD in Newly Diagnosed Rheumatoid Arthritis	Recruiting	N/A	300	Europe	pulmonary function tests, High-resolution CT scanner	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	Rheumatoid Arthritis	12/22	12/22
Dahlqvist, Caroline
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease	Recruiting	3	440	Europe, Canada, Japan, US, RoW	Belimumab, BENLYSTA, GSK1550188, Placebo	GlaxoSmithKline	Lung Diseases, Interstitial	10/28	12/28
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis	Active, not recruiting	3	597	Europe, RoW	Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer	United Therapeutics	Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease	07/25	07/25
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27
Mackiewicz, Barbara
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27
NCT03870828: Clinical Characteristics of Interstitial Pneumonia With Autoimmune Features (IPAF) - a Multicenter Prospective Study	Not yet recruiting	N/A	210	Europe	Bronchoalveolar lavage and taking bronchial mucosa samples, 6minute walk test, 6MWT, Arterial blood gas, ABG, Blood drawing	Medical University of Silesia	Interstitial Lung Disease, Interstitial Pneumonia, Interstitial Fibrosis, Autoimmune Diseases	02/20	12/25
Tzouvelekis, Argyrios
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Data from MATINEE trial for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD	Completed	3	806	Europe, Canada, US, RoW	Placebo, Mepolizumab	GlaxoSmithKline, PPD DEVELOPMENT, LP	Pulmonary Disease, Chronic Obstructive	08/24	08/24
DESTINY, NCT05334368: Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial	Recruiting	3	123	Europe, Japan, US, RoW	Depemokimab, Placebo	GlaxoSmithKline	Hypereosinophilic Syndrome	11/26	11/26
PRECISION, NCT05926505 / 2023-000102-25: Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome	Recruiting	2/3	182	Europe	Placebo, Anakinra 149 MG/ML Prefilled Syringe [Kineret]	Hellenic Institute for the Study of Sepsis, Hellenic Institute for the Study of Sepsis	Post-Acute COVID-19 Syndrome, Post-Acute COVID-19, Long COVID	08/25	08/25
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27
Patyk, Iwona
BBT877-IPF-004, NCT05483907: To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF Jul 2023 - Dec 2023 : Interim data for the treatment of IPF Initiation of trial in idiopathic pulmonary fibrosis Nov 2022 - Nov 2022: Initiation of trial in idiopathic pulmonary fibrosis	Completed	2	129	Europe, US, RoW	BBT-877, Placebo	Bridge Biotherapeutics, Inc.	Idiopathic Pulmonary Fibrosis	01/25	02/25
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27
Gauthier, Patrice
NCT06372496: Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma	Active, not recruiting	4	1358	Canada, Japan, US, RoW	Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists	GlaxoSmithKline	Asthma	11/25	03/26
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease	Recruiting	3	440	Europe, Canada, Japan, US, RoW	Belimumab, BENLYSTA, GSK1550188, Placebo	GlaxoSmithKline	Lung Diseases, Interstitial	10/28	12/28
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27
Breyer, Marie-Kathrin
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27
NCT01727518: The Austrian LEAD (Lung hEart sociAl boDy) Study	Active, not recruiting	N/A	14966	Europe	As the LEAD study is an observational cohort study, there is no intervention to report.	Ludwig Boltzmann Institute for Lung Health	Respiration Disorders, Body Composition, Beneficial, Metabolic Health	10/16	10/28
NCT06522347: Mycobacteria Registry Study: Prospective Observational Study in Austria	Recruiting	N/A	1000	Europe		Ludwig Boltzmann Institute for Lung Health, Sigmund Freud PrivatUniversitat	Non-Tuberculous Mycobacterial Pneumonia, Tuberculosis	12/53	12/53
NCT06522334: Interstitial Lung Disease Registry Study: Prospective and Retrospective Observational Study in Austria	Recruiting	N/A	400	Europe		Ludwig Boltzmann Institute for Lung Health	Interstitial Lung Disease	02/34	02/34
Glaeser, Sven
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27
Tomos, Ioannis
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27
Manali, Efrosyni
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27